Sirtex: Interim result 2013

Fast-growing companies rarely rise in a straight line. Jason Prowd outlines why we're still backing Sirtex following a less than impressive interim result.

Sirtex Medical posted another record half of dose sales, which rose 31% to 3,522 for the half-year ended 31 December. This translated into revenue of $46.0m, up 25% for the period, and net profit of $7.8m, a rise of 28%. Earnings per share followed suit, rising 26% to 13.6 cents. As in the previous year, no interim dividend will be paid (although a final dividend of 10 cents was paid during the half, up from 7 cents in 2011).


SMS Code Sent…

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Looks you are already a member. Please enter your password to proceed

Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

Related Articles